Neurology

Back to articles

Early use of high-efficacy disease-modifying MS therapies may be better than escalation

KEY POINT

People with multiple sclerosis (MS) who were prescribed high-efficacy disease-modifying therapies (DMTs) as initial therapy had better long-term outcomes than those prescribed moderate-efficacy DMTs as initial therapy, according to data from an observational study published in JAMA Neurology.